JADPRO Live 2017 Educational Activities

These educational activities are based on presentations from JADPRO Live at APSHO 2017. Access the full-length video presentation, the slide deck, transcript, and the entire lecture as a podcast. Click on any of the video presentations below to get started!

All  |  AML  |  AML  |  BRCA  |  Immunotherapy  |  Immunotherapy  |  Immunotherapy  |  Immunotherapy  |  PARP  |  CML  |  MDS  |  MPN  |  Colon Cancer  |  Colorectal Cancer  |  Lynch Syndrome  |  mCRC  |  MSI-H  |  Rectal Cancer  |  CAR T-Cell Therapy  |  irAEs  |  irAEs  |  Side Effect Management  |  ALK Positive NSCLC  |  EGFR Resistance  |  Lymphomas and Leukemias  |  Bladder Cancer  |  Urothelial Carcinoma  |  GIST  |  Leiomyosarcoma  |  Soft Tissue Sarcomas  |  Surgery  |  Drug Development  |  MRD  |  Multiple Myeloma  |  Oral Therapies  |  Risk Stratification  |  Adjuvant Treatment  |  Breast Cancer  |  Diarrhea  |  HER2 Positive Breast Cancer
New Drug Updates in Solid Tumors: PARP Inhibitors in Ovarian Cancer, Immunotherapeutics, and Other Agents

This activity is supported by independent educational grants from AstraZeneca, Merck Sharp & Dohme Corp, Novartis Pharmaceuticals Corporation, Puma Biotechnology, Takeda Oncology, and TESARO, Inc.

New Drug Updates in Solid Tumors: PARP Inhibitors in Ovarian Cancer, Immunotherapeutics, and Other Agents

Get updated on the latest drug treatments for solid tumors and the clinical trial data behind their FDA approvals. And importantly, learn how to spot the common adverse side effects from these newly approved treatments and how to help patients manage them.

Posted: January 22, 2017 / Expires: January 22, 2018

This certified activity has expired but you may watch the video without claiming credit.

Watch Video Without Claiming Credit

New Drug Updates in Solid Tumors: PARP Inhibitors in Ovarian Cancer, Immunotherapeutics, and Other Agents

This activity is supported by independent educational grants from AstraZeneca, Merck Sharp & Dohme Corp, Novartis Pharmaceuticals Corporation, Puma Biotechnology, Takeda Oncology, and TESARO, Inc.

New Drug Updates in Solid Tumors: PARP Inhibitors in Ovarian Cancer, Immunotherapeutics, and Other Agents

Get updated on the latest drug treatments for solid tumors and the clinical trial data behind their FDA approvals. And importantly, learn how to spot the common adverse side effects from these newly approved treatments and how to help patients manage them.

Posted: January 22, 2017 / Expires: January 22, 2018

This certified activity has expired but you may watch the video without claiming credit.

Watch Video Without Claiming Credit

Hereditary Aspects of Colorectal Cancer

This activity is supported by an independent educational grant from Merck Sharp & Dohme Corp.

Hereditary Aspects of Colorectal Cancer

Learn about Lynch syndrome and other hereditary colorectal cancer syndromes, in addition to which patients are at risk, how to screen for these syndromes, and the relationship between biomarkers and targeted therapies for colorectal cancer. With 95% of Americans with Lynch syndrome unaware of their condition, it is vital that advanced practitioners in oncology be well-versed in the hereditary aspects of colorectal cancer to ensure patients are diagnosed effectively and receive the appropriate treatment.

Posted: January 22, 2018 / Expires: January 22, 2019

This certified activity has expired but you may watch the video without claiming credit.

Watch Video Without Claiming Credit

Managing Side Effects of Cancer Patients Treated With Immunotherapy

This activity is supported by independent educational grants from AstraZeneca, Bristol-Myers Squibb, and Merck Sharp & Dohme Corp.

Managing Side Effects of Cancer Patients Treated With Immunotherapy

Learn how to identify, assess, and manage the possible side effects from cancer immunotherapy, as well as how to educate patients on what to expect from treatment. With the constantly growing list of FDA-approved immunotherapies for cancer, it is vital that advanced practitioners in oncology remain up-to-date on this cutting-edge treatment area, including the questions that research has yet to answer.

Posted: January 22, 2018 / Expires: January 22, 2019

This certified activity has expired but you may watch the video without claiming credit.

Watch Video Without Claiming Credit

Advances in the Management of Patients with Urothelial Carcinomas of the Bladder

This activity is supported by an independent educational grant from Merck Sharp & Dohme Corp.

Advances in the Management of Patients with Urothelial Carcinomas of the Bladder

Get an update on the state of chemotherapy and immunotherapy for the treatment of urothelial carcinomas of the bladder. Learn how these therapies combat the various types of urothelial carcinomas and how to identify their most common side effects, including immune-related adverse effects from immunotherapy.

Posted: January 22, 2018 / Expires: January 22, 2019

This certified activity has expired but you may watch the video without claiming credit.

Watch Video Without Claiming Credit

New Drug Updates in Solid Tumors: PARP Inhibitors in Ovarian Cancer, Immunotherapeutics, and Other Agents

This activity is supported by independent educational grants from AstraZeneca, Merck Sharp & Dohme Corp, Novartis Pharmaceuticals Corporation, Puma Biotechnology, Takeda Oncology, and TESARO, Inc.

New Drug Updates in Solid Tumors: PARP Inhibitors in Ovarian Cancer, Immunotherapeutics, and Other Agents

Get updated on the latest drug treatments for solid tumors and the clinical trial data behind their FDA approvals. And importantly, learn how to spot the common adverse side effects from these newly approved treatments and how to help patients manage them.

Posted: January 22, 2017 / Expires: January 22, 2018

This certified activity has expired but you may watch the video without claiming credit.

Watch Video Without Claiming Credit

Hereditary Aspects of Colorectal Cancer

This activity is supported by an independent educational grant from Merck Sharp & Dohme Corp.

Hereditary Aspects of Colorectal Cancer

Learn about Lynch syndrome and other hereditary colorectal cancer syndromes, in addition to which patients are at risk, how to screen for these syndromes, and the relationship between biomarkers and targeted therapies for colorectal cancer. With 95% of Americans with Lynch syndrome unaware of their condition, it is vital that advanced practitioners in oncology be well-versed in the hereditary aspects of colorectal cancer to ensure patients are diagnosed effectively and receive the appropriate treatment.

Posted: January 22, 2018 / Expires: January 22, 2019

This certified activity has expired but you may watch the video without claiming credit.

Watch Video Without Claiming Credit

Hereditary Aspects of Colorectal Cancer

This activity is supported by an independent educational grant from Merck Sharp & Dohme Corp.

Hereditary Aspects of Colorectal Cancer

Learn about Lynch syndrome and other hereditary colorectal cancer syndromes, in addition to which patients are at risk, how to screen for these syndromes, and the relationship between biomarkers and targeted therapies for colorectal cancer. With 95% of Americans with Lynch syndrome unaware of their condition, it is vital that advanced practitioners in oncology be well-versed in the hereditary aspects of colorectal cancer to ensure patients are diagnosed effectively and receive the appropriate treatment.

Posted: January 22, 2018 / Expires: January 22, 2019

This certified activity has expired but you may watch the video without claiming credit.

Watch Video Without Claiming Credit

Hereditary Aspects of Colorectal Cancer

This activity is supported by an independent educational grant from Merck Sharp & Dohme Corp.

Hereditary Aspects of Colorectal Cancer

Learn about Lynch syndrome and other hereditary colorectal cancer syndromes, in addition to which patients are at risk, how to screen for these syndromes, and the relationship between biomarkers and targeted therapies for colorectal cancer. With 95% of Americans with Lynch syndrome unaware of their condition, it is vital that advanced practitioners in oncology be well-versed in the hereditary aspects of colorectal cancer to ensure patients are diagnosed effectively and receive the appropriate treatment.

Posted: January 22, 2018 / Expires: January 22, 2019

This certified activity has expired but you may watch the video without claiming credit.

Watch Video Without Claiming Credit

Hereditary Aspects of Colorectal Cancer

This activity is supported by an independent educational grant from Merck Sharp & Dohme Corp.

Hereditary Aspects of Colorectal Cancer

Learn about Lynch syndrome and other hereditary colorectal cancer syndromes, in addition to which patients are at risk, how to screen for these syndromes, and the relationship between biomarkers and targeted therapies for colorectal cancer. With 95% of Americans with Lynch syndrome unaware of their condition, it is vital that advanced practitioners in oncology be well-versed in the hereditary aspects of colorectal cancer to ensure patients are diagnosed effectively and receive the appropriate treatment.

Posted: January 22, 2018 / Expires: January 22, 2019

This certified activity has expired but you may watch the video without claiming credit.

Watch Video Without Claiming Credit

Hereditary Aspects of Colorectal Cancer

This activity is supported by an independent educational grant from Merck Sharp & Dohme Corp.

Hereditary Aspects of Colorectal Cancer

Learn about Lynch syndrome and other hereditary colorectal cancer syndromes, in addition to which patients are at risk, how to screen for these syndromes, and the relationship between biomarkers and targeted therapies for colorectal cancer. With 95% of Americans with Lynch syndrome unaware of their condition, it is vital that advanced practitioners in oncology be well-versed in the hereditary aspects of colorectal cancer to ensure patients are diagnosed effectively and receive the appropriate treatment.

Posted: January 22, 2018 / Expires: January 22, 2019

This certified activity has expired but you may watch the video without claiming credit.

Watch Video Without Claiming Credit

Hereditary Aspects of Colorectal Cancer

This activity is supported by an independent educational grant from Merck Sharp & Dohme Corp.

Hereditary Aspects of Colorectal Cancer

Learn about Lynch syndrome and other hereditary colorectal cancer syndromes, in addition to which patients are at risk, how to screen for these syndromes, and the relationship between biomarkers and targeted therapies for colorectal cancer. With 95% of Americans with Lynch syndrome unaware of their condition, it is vital that advanced practitioners in oncology be well-versed in the hereditary aspects of colorectal cancer to ensure patients are diagnosed effectively and receive the appropriate treatment.

Posted: January 22, 2018 / Expires: January 22, 2019

This certified activity has expired but you may watch the video without claiming credit.

Watch Video Without Claiming Credit

Managing Side Effects of Cancer Patients Treated With Immunotherapy

This activity is supported by independent educational grants from AstraZeneca, Bristol-Myers Squibb, and Merck Sharp & Dohme Corp.

Managing Side Effects of Cancer Patients Treated With Immunotherapy

Learn how to identify, assess, and manage the possible side effects from cancer immunotherapy, as well as how to educate patients on what to expect from treatment. With the constantly growing list of FDA-approved immunotherapies for cancer, it is vital that advanced practitioners in oncology remain up-to-date on this cutting-edge treatment area, including the questions that research has yet to answer.

Posted: January 22, 2018 / Expires: January 22, 2019

This certified activity has expired but you may watch the video without claiming credit.

Watch Video Without Claiming Credit

Advances in the Management of Patients with Urothelial Carcinomas of the Bladder

This activity is supported by an independent educational grant from Merck Sharp & Dohme Corp.

Advances in the Management of Patients with Urothelial Carcinomas of the Bladder

Get an update on the state of chemotherapy and immunotherapy for the treatment of urothelial carcinomas of the bladder. Learn how these therapies combat the various types of urothelial carcinomas and how to identify their most common side effects, including immune-related adverse effects from immunotherapy.

Posted: January 22, 2018 / Expires: January 22, 2019

This certified activity has expired but you may watch the video without claiming credit.

Watch Video Without Claiming Credit

Managing Side Effects of Cancer Patients Treated With Immunotherapy

This activity is supported by independent educational grants from AstraZeneca, Bristol-Myers Squibb, and Merck Sharp & Dohme Corp.

Managing Side Effects of Cancer Patients Treated With Immunotherapy

Learn how to identify, assess, and manage the possible side effects from cancer immunotherapy, as well as how to educate patients on what to expect from treatment. With the constantly growing list of FDA-approved immunotherapies for cancer, it is vital that advanced practitioners in oncology remain up-to-date on this cutting-edge treatment area, including the questions that research has yet to answer.

Posted: January 22, 2018 / Expires: January 22, 2019

This certified activity has expired but you may watch the video without claiming credit.

Watch Video Without Claiming Credit

Advances in the Management of Patients with Urothelial Carcinomas of the Bladder

This activity is supported by an independent educational grant from Merck Sharp & Dohme Corp.

Advances in the Management of Patients with Urothelial Carcinomas of the Bladder

Get an update on the state of chemotherapy and immunotherapy for the treatment of urothelial carcinomas of the bladder. Learn how these therapies combat the various types of urothelial carcinomas and how to identify their most common side effects, including immune-related adverse effects from immunotherapy.

Posted: January 22, 2018 / Expires: January 22, 2019

This certified activity has expired but you may watch the video without claiming credit.

Watch Video Without Claiming Credit

Advances in the Management of Patients with Urothelial Carcinomas of the Bladder

This activity is supported by an independent educational grant from Merck Sharp & Dohme Corp.

Advances in the Management of Patients with Urothelial Carcinomas of the Bladder

Get an update on the state of chemotherapy and immunotherapy for the treatment of urothelial carcinomas of the bladder. Learn how these therapies combat the various types of urothelial carcinomas and how to identify their most common side effects, including immune-related adverse effects from immunotherapy.

Posted: January 22, 2018 / Expires: January 22, 2019

This certified activity has expired but you may watch the video without claiming credit.

Watch Video Without Claiming Credit


Copyright © 2010-2019 Harborside Press, LLC All rights reserved.               
Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact | Copyright Notice/Disclaimer | Subscribe
Bot trap - Don't go here
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.